Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 416 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: SARS-CoV-2 Acute Respiratory Disease Clear all
Completed Phase 2 Interventional

RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)

NCT06305806
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
Ivabradine, Ivabradine Placebo, Coordinated Care, Usual Care
Drug · Behavioral
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 8, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729593
View directory record Official record
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 8, 2026, 2:52 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota

NCT04473183
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, SARS-CoV-2, Corona Virus Infection
Interventions
Specimen Collection, Surveys
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 8, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19

NCT04570384
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure
Interventions
L-Citrulline, Placebo
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 8, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection

NCT04818216
View directory record Official record
Conditions
SARS-CoV-2 Infection, Acute Kidney Injury
Interventions
Placebo, Nicotinamide riboside
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
New York, New York • San Antonio, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 8, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cyclosporine For The Treatment Of COVID-19(+)

NCT04492891
View directory record Official record
Conditions
SARS (Disease)
Interventions
Cyclosporine, Standard of Care Treatment
Drug · Other
Lead sponsor
Bryan Burt, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 8, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effects of Immulina TM Supplements With PASC Patients

NCT05524532
View directory record Official record
Conditions
Post Acute COVID-19 Syndrome
Interventions
Immulina TM, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
8
States / cities
Honolulu, Hawaii • Baton Rouge, Louisiana • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 8, 2026, 2:52 PM EDT
Recruiting Phase 2 Interventional

Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS

NCT07189936
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS), SARS CoV 2 Infection, Long COVID19
Interventions
To Measure levels of circulating monocyte/ T cell doublets at Baseline, To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment, To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment, To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA, To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo, To Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA, To Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo
Drug · Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 8, 2026, 2:52 PM EDT
Completed No phase listed Observational

EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID )

NCT04445493
View directory record Official record
Conditions
Stroke, Acute, COVID-19
Interventions
MindRhythm Harmony
Device
Lead sponsor
MindRhythm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 8, 2026, 2:52 PM EDT
Enrolling by invitation No phase listed Observational

Microbial and Cytokine Signatures in Long COVID Patients

NCT07074158
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Not listed
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
150 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 8, 2026, 2:52 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults

NCT05258669
View directory record Official record
Conditions
COVID-19
Interventions
BBV152
Biological
Lead sponsor
Ocugen
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Tempe, Arizona • Miami, Florida • Miami Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 8, 2026, 2:52 PM EDT
Terminated Phase 1 Interventional Results available

Camostat With Bicalutamide for COVID-19

NCT04652765
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, Coronavirus Infection
Interventions
Camostat Mesilate, Bicalutamide 150 mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 8, 2026, 2:52 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

NCT04432298
View directory record Official record
Conditions
COVID-19
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Detroit, Michigan • Greensboro, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 8, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Results available

Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19

NCT04809974
View directory record Official record
Conditions
Covid19, Sequelae of; Infection, Cognitive Symptom
Interventions
Niagen
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 8, 2026, 2:52 PM EDT
Not listed No phase listed Observational

Effect of Apollo Wearable on Long COVID-19 Symptoms.

NCT06097442
View directory record Official record
Conditions
Post-acute Sequelae of SARS-COV-2 Infection
Interventions
Not listed
Lead sponsor
The Board of Medicine
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 8, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

RECOVER-AUTONOMIC Platform Protocol

NCT06305780
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care
Drug
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
50
States / cities
Opelika, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 8, 2026, 2:52 PM EDT
Completed No phase listed Observational

Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome

NCT05013723
View directory record Official record
Conditions
Post-acute COVID-19 (PACS), or "long COVID" Syndrome
Interventions
Surveys
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 8, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

NCT04510194
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Metformin, Placebo, Fluvoxamine, Ivermectin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 85 Years
Enrollment
1,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Sylmar, California • Aurora, Colorado • Golden, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 8, 2026, 2:52 PM EDT
No Longer Available No phase listed Expanded access

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

NCT04355494
View directory record Official record
Conditions
COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
eculizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Newton, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 8, 2026, 2:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR

NCT04604145
View directory record Official record
Conditions
SARS-CoV Infection, Polymerase Chain Reaction, Laboratory Testing
Interventions
SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen
Diagnostic Test
Lead sponsor
David Grant U.S. Air Force Medical Center
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Travis Air Force Base, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 8, 2026, 2:52 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants

NCT07093580
View directory record Official record
Conditions
Healthy Participants
Interventions
S-892216-LAI, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 8, 2026, 2:52 PM EDT
Recruiting Phase 3 Interventional

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287
View directory record Official record
Conditions
Long COVID, Sars-CoV-2 Infection, Coronavirus Infections, COVID-19
Interventions
Baricitinib, Placebo
Drug · Other
Lead sponsor
Wes Ely
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 8, 2026, 2:52 PM EDT
Suspended Early Phase 1 Interventional

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

NCT06171152
View directory record Official record
Conditions
Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission
Interventions
Liraglutide Pen Injector [Saxenda], Medication Diary
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 8, 2026, 2:52 PM EDT
Terminated Not applicable Interventional

CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19

NCT05530317
View directory record Official record
Conditions
Long COVID, COVID-19
Interventions
Cardiac Rehabilitation
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 8, 2026, 2:52 PM EDT